Dear E,
If you need to start your clinical study quickly, discover how biotechs are saving up to a year in regulatory timelines and considerable costs by conducting their trials in Australia.
The Avance Clinical specialist CRO team will ensure you access all of Australia's unique clinical development opportunities including up to 43.5% cash rebate on clinical costs.
Other proven benefits include:
1. No IND required
Our biotech clients start their Phase I without having to wait for an IND, saving up to a year in regulatory timelines and considerable costs.
2. Rapid IRB/EC approval
Our clients are currently experiencing a 3-week IRB/EC turnaround due to the supportive regulatory and clinical environment, and Avance Clinical's 25 years of experience. Watch video
3. World-class data
Avance Clinical data is accepted by all the major regulatory authorities including the FDA and EMA.
4. COVID-19 success
With almost 80% of adults vaccinated, Australia has prioritized clinical research as an essential service which supports Avance Clinical's biotech clients, clinical sites, and patients seeking access to therapies.
5. Proven site network across Australia and New Zealand
Avance Clinical has a powerful Australian and New Zealand network of proven PIs and clinical sites.
Please contact one of our team to discuss your preclinical or clinical program.
You can also download our latest Frost & Sullivan APAC CRO Report here.
Sincerely,
Yvonne Lungershausen
Avance Clinical CEO
The award-winning APAC CRO
"Having conducted several Phase I studies in Australia it made sense to continue in the country with our Phase II program, particularly given the high-quality support we have received from our CRO." Atossa Therapeutics Inc.
| 
